MBRX · Moleculin Biotech, Inc. · Documents
$6.50
+0.61 (+10.36%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, the Company had an accumulated deficit of $226.5 million since inception and had not yet generated any revenues from operations. Additionally, management anticipates that its cash on hand of $7.3 million as of June 30, 2026, is not sufficient to fund its planned operations for a period of at least one year from when these condensed consolidated financial statements are issued. These factors raise substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$5.74M
Shares
973,869
Volume · Oct 23
27.74K
Avg daily vol (4 sessions)
65.18K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Moleculin Biotech, Inc.’s board approved a 1-for-20 reverse stock split, effective 12:01 a.m. Eastern Time on October 20, 2026, reducing outstanding common stock from approximately 20.91 million shares to approximately 1.05 million shares; authorized common stock remains 500 million shares. | 2026-10-20 | 2026-10-16 | |
| 8-K | Moleculin Biotech, Inc. furnished an investor presentation dated October 16, 2026, posted on its website and attached as Exhibit 99.1. | 2026-10-16 | — | |
| 8-K | Moleculin Biotech, Inc. stockholders approved a 3,861,894-share increase in its 2024 Equity Plan, bringing shares to 3,875,999. They authorized the Board to effect a reverse stock split at a ratio from 1-for-2 to 1-for-20, but rejected eliminating supermajority voting requirements. | 2026-10-09 | — | |
| 8-K | — | 2026-10-05 | — | |
| 8-K | — | 2026-09-29 | — | |
| 8-K | — | 2026-09-28 | — | |
| 8-K | — | 2026-09-25 | — | |
| 8-K | — | 2026-09-23 | — | |
| 8-K | — | 2026-09-18 | 2026-09-15 | |
| 8-K | — | 2026-09-14 | — | |
| Investor Event Transcript | — | 2026-09-11 | 2026-09-30 | |
| 8-K | — | 2026-08-31 | — | |
| DEF 14A | — | 2026-08-24 | 2026-10-09 | |
| DEFA14A | — | 2026-08-24 | — | |
| PRE 14A | — | 2026-08-14 | 2026-10-09 | |
| 8-K | — | 2026-08-14 | — | |
| 10-Q | — | 2026-08-13 | 2026-06-30 | |
| 8-K | — | 2026-08-03 | 2026-07-31 | |
| 8-K | — | 2026-07-31 | — | |
| S-1/A | — | 2026-07-31 | — | |
| S-1/A | — | 2026-07-30 | — | |
| S-1 | — | 2026-07-29 | — | |
| 8-K | — | 2026-06-30 | — | |
| 8-K | — | 2026-06-30 | — | |
| 8-K | — | 2026-06-05 | — | |
| 8-K | — | 2026-05-29 | — | |
| 8-K | — | 2026-05-26 | — | |
| 8-K | — | 2026-05-22 | — | |
| 8-K | — | 2026-05-15 | — | |
| 10-Q | — | 2026-05-14 | 2026-03-31 | |
| 8-K | — | 2026-05-13 | — | |
| 8-K | — | 2026-05-12 | — | |
| 8-K | — | 2026-05-08 | — | |
| 8-K | — | 2026-04-23 | — | |
| 8-K | — | 2026-04-15 | — | |
| 10-K/A | — | 2026-04-14 | 2025-12-31 | |
| S-3 | — | 2026-03-27 | — | |
| 8-K | — | 2026-03-23 | — | |
| 8-K | — | 2026-03-19 | — | |
| 8-K | — | 2026-03-19 | — | |
| 10-K | — | 2026-03-18 | 2025-12-31 | |
| DEF 14A | — | 2026-03-09 | 2026-04-15 | |
| PRE 14A | — | 2026-02-26 | 2026-04-15 | |
| 8-K | — | 2026-02-20 | 2026-02-19 | |
| 8-K | — | 2026-02-18 | — | |
| 8-K | — | 2026-02-18 | — | |
| 8-K | — | 2026-02-17 | — | |
| 8-K | — | 2026-02-05 | — | |
| 8-K | — | 2026-01-20 | — | |
| 8-K | — | 2026-01-13 | — |
Showing 1–50 of 407 filings